Cytek Biosciences, Inc. Common Stock earnings per share and revenue
On Jan 28, 2026, CTKB reported earnings of -- USD per share (EPS) for Q4 25, -- the estimate of -0.04 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 58.33 million, with a --% difference. The market reacted with a -3.91% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 7 analysts forecast an EPS of -0.09 USD, with revenue projected to reach 45.28 million USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
What were Cytek Biosciences, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Cytek Biosciences, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Cytek Biosciences, Inc. Common Stock's Q4 2025 earnings?
The stock price moved down -3.91%, changed from $5.62 before the earnings release to $5.40 the day after.
When is Cytek Biosciences, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 06, 2026.
What are the forecasts for Cytek Biosciences, Inc. Common Stock's next earnings report?
Based on 7
analysts, Cytek Biosciences, Inc. Common Stock is expected to report EPS of -$0.09 and revenue of $45.28M for Q1 2026.